Vimarsana
Biggest News Aggregation in the World

Peterb Bach News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peterb Bach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peterb Bach Today - Breaking & Trending Today

Can Late-Stage Cancer Incidence Serve as an Endpoint for Screening Trials? - Vimarsana News

Can Late-Stage Cancer Incidence Serve as an Endpoint for Screening Trials?

Study shows it may be an alternative to cancer-specific mortality for some cancers, but not all

City of Hope and DELFI Diagnostics announce collaboration to improve lung cancer screening rates in underserved areas of Los Angeles - Vimarsana News

City of Hope and DELFI Diagnostics announce collaboration to improve lung cancer screening rates in underserved areas of Los Angeles

/PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, and DELFI Diagnostics, Inc., a developer of...

The exploited 340B program is the real horror this Halloween | Guest Commentary - Vimarsana News

The exploited 340B program is the real horror this Halloween | Guest Commentary

Guest Commentary: Handing the discounts to patients rather than handing out profits to hospitals and contract pharmacies would be a sweet treat not just on Halloween but throughout the year.

Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study - Vimarsana News

Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study

Objective To estimate the association between oncologists’ receipt of payments from the pharmaceutical industry and delivery of non-recommended or low value interventions among their patients. Design Cohort study. Setting Fee-for-service Medicare claims. Participants Medicare beneficiaries with a diagnosis of incident cancer (new occurrence of a cancer diagnosis code in proximity to claims for cancer treatment, and no such diagnosis codes during a ≥1 year washout period) during 2014-19, who met additional requirements identifying them as at risk for one of four non-recommended or low value...

Source: bmj.com
DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection - Vimarsana News

DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection

/PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to detect cancer, announced today that the company...